In this study, we characterized a novel function of carboxypeptidase N1 (Cpn1) in the vasculature. We show that cpn1 mRNA is expressed in developing vessels. The knockdown of cpn1 by morpholino injection impairs the growth of intersegmental vessels (ISV) and caudal vein plexus (CVP), suggesting the role of cpn1 in vascular development. We showed that vascular defects are not caused by cell death but are due to the impairment of migration and proliferation. Consistent with vascular growth defects, loss of cpn1 affects the expression of the vascular markers flt4, mrc1, flk, stabilin, and ephrinb2. Furthermore, the overexpression of cpn1 impaired the growth of ISV and CVP, but the remodeling expression of vascular markers was different from the knockdown of cpn1, indicating the differential regulation mechanisms in cpn1-overexpressing embryos. We examine the interaction between cpn1 and multiple signals and observed that cpn1 is regulated by Notch/VEGF signals for ISV growth and likely regulates BMP signals for CVP patterning. In conclusion, we demonstrate that cpn1 has a critical role in the vascular development of zebrafish. We also reveal a fine-tune regulation of cpn1 that controls vascular patterning mediated by multiple signals.
Results
Cpn1 is conserved and cpn1 mRNA is expressed in developing vessels. In our previous study, we identified the function of the transcription factors Isl2 and Nr2f1b in the vasculature mediated by Notch signals 18, 19 . Our Isl2/Nr2f1b transcriptomal analysis suggested that cpn1 acts a potential function in the vasculature. In this study, we characterized a novel function of cpn1 that contributes to vessel growth and patterning. Cpn1 encodes carboxypeptidase, a plasma metalloprotease; however, no study has yet reported the role of cpn1 in vascular development. Thus, we aligned the sequences of zebrafish Cpn1 with those of the humans (Homo sapiens), mice (Mus musculus), and chickens (Gallus gallus) using ClustalW2 software. The sequence alignment revealed that the zebrafish Cpn1 protein contains 450 amino acids with the N-terminal M14 family of the metallocarboxypeptidase domain and C-terminal peptidase-associated domain (sFig. 1A,B). A phylogenetic analysis of the amino acid sequences of Cpn1 proteins from different species demonstrated that the similarity of the amino acid sequences of zebrafish Cpn1 to those of humans, mice, and chickens are 69.3, 65.8, and 67.3, respectively; which is highly conserved among these vertebrates (sFig. 1C).
To explore the potential role of cpn1 in the vascular development of zebrafish, we examined the expression pattern of cpn1 mRNA during zebrafish development through in situ hybridization. We observed cpn1 expression in 15-18 S stages in the lateral plate mesoderm (lpm), hindbrain (h), and telencephalon (t) (Fig. 1A,A′) . At 24 hpf, cpn1 was expressed in the vessels (both dorsal aorta (da) and posterior cardinal vein (pcv)), ISV and CVP, as depicted in the lateral view or cross-section ( Fig. 1B-D Knockdown of cpn1 causes vascular defects during zebrafish development. To identify the role of cpn1 in vascular development, we used Tg (kdrl:eGFP) la116 embryos expressing GFP in endothelial cells. After the knockdown of cpn1 through the administration of a morpholino injection into the embryos, we observed vascular defects in cpn1 morphants. We knocked down cpn1 expression by injecting 3.4 ng of ATG morpholino to block the translational site (cpn1 ATG MO). The loss of cpn1 caused the following 2 marked vascular phenotypes: ISV growth defects and CVP mispatterning. Compared with 90% complete ISVs in uninjected controls (n = 29 embryos), we observed only 45% complete ISVs (n = 31 embryos) with slightly edema in cpn1 ATG morphants at 30 hpf ( Fig. 2A-E ). In addition, we observed defects in CVP formation as a second phenotype. From 30-48 hpf in wt fish, endothelial cells in the CVP region underwent angiogenic sprouting and migration, and formed a honeycomb structure or a loop ( Fig. 2F-I) . The sprouting and loop structure formation in CVP was decreased in the cpn1 morphants as compared to the uninjected controls at 30 hpf (Fig. 2F,G) ; and the honeycomb-like loop at CVP was quantified at 48 hpf (n = 32 in wt and n = 33 in cpn1 morphants; Fig. 2H-J) . These data indicate that cpn1 may play a critical role in controlling the behavior of endothelial tip cells and in the regulation of ISV and CVP formation during angiogenesis. Furthermore, since pericardial edema and circulation blockage are common secondary effects of blood vessel impairment, we examined whether these side effects occurred in cpn1 morphants. We observed limited blood flow in the trunk of cpn1 morphants at 48 hpf ( Fig. 2K,L) . Approximately 60% cpn1 morphant embryos had circulation in the axial vessels and only about 10% cpn1 morphant embryos had circulation in ISVs ( Fig. 2M , n = 39 in control and n = 28 in cpn1 ATG MO). At 72 hpf, cpn1 morphants showed an increasing edema ~90% compared to the controls ( Fig. 2N -P, n = 127 in control and n = 50 in cpn1 ATG MO), which was likely caused by circulation defects. The data are consistent with vascular defects in the knock-downed cpn1 embryos.
Specificity of cpn1 knockdown by morpholino.
We observed that the loss of cpn1 causes vascular defects by targeting the translation initiation site (cpn1 ATG MO; Fig. 2 ). To investigate whether the phenotype of cpn1 morpholino knockdown is loss-of-cpn1 specific, we examined the effects of additional morpholino blocking the splicing site at the exon1-intron1 boundary (cpn1 e1i1 MO). Our results showed similar vascular defects in cpn1 e1i1 MO (sFig. 2) compared to cpn1 ATG morphants. We observed and quantified vascular defects in CVP Scientific RepoRts | 7: 1852 | DOI:10.1038/s41598-017-01976-x formation and ISV growth in cpn1 e1i1 MO at 30hpf and 48hpf (sFig. 2C-J). Furthermore, we examined the efficiency of cpn1 e1i1 morpholino knockdown. The RT-PCR analysis revealed that the injection of 5.1 ng or 15.8 ng of cpn1 e1i1 morpholino dose-dependently reduced the normal fragment of cpn1 (sFig. 2K,L), indicating that the loss of cpn1 expression is caused by morpholino inhibition. The data suggests that the phenotype of cpn1 morpholino knockdown is specific. Furthermore, to test sequence targeting specificity of cpn1 ATG morpholinos, we made a cpn-atg-GFP fusion construct containing the cpn1 ATG MO targeting sequence. Embryos co-injected with mRNA from the cpn1-atg-GFP construct and cpn1 ATG MO reduced and/or blocked the GFP signal in the embryos at 24 hpf (sFig. 3A,B), which suggests the specificity of ATG morpholino targeting. To confirm the efficacy of morpholino knockdown, we performed a Western blot analysis and showed a significant reduction of Cpn1 protein levels in both ATG and splicing morpholinos injected embryos (sFig. 3C). These data are consistent with the efficacy and specificity of cpn1 knockdown by morpholino.
Moreover, injection of 10 ng control morpholino did not cause vascular defects in ISV and CVP (sFig. 4A,B), which is consistent with the phenotypic specificity of morpholino knockdown of cpn1. We also assessed the gross developmental process in cpn1 morphants at 24-25 hpf and showed development in other tissue/organs is unaffected because the knockdown of cpn1 did not alter the expression of cmlc2 (heart marker), gata6 (heart and gut marker), myoD (somite marker), and sox3 (neural markers) (sFig. 5A-H). Meanwhile, we measured the heart rate by direct visual examination of ventricle beating in embryos at 24-25 hpf and found no difference between the uninjected controls and cpn1 morphants (sFig. 5I), suggesting the knockdown of cpn1 did not cause developmental delay.
Knockdown of cpn1 impairs the growth of ISV cells. The knockdown of cpn1 caused vascular growth
defects, suggesting the interruption of endothelial cell behaviors such as migration, proliferation, or an increase of cell death. To test these possibilities, we first performed a TUNEL assay and Acridine Orange (AO) staining to detect apoptotic cells. We observed cpn1 morphants have an increase in apoptotic cells at the epidermis of dorsal region compared to wild-type embryos; however, morpholino-induced cell death did not show in the vessel region of the trunk (Fig. 3A-D ). In addition, co-injection of cpn1 MO with p53 morpholino showed a reduction of apoptotic cells but still caused vascular defects in ISV and CVP (Fig. 3E ). The data suggest that vascular defects are not due to endothelial cell death.
We investigated whether the loss of cpn1 affects cell proliferation by determining the number of endothelial cells per ISV in Tg (kdrl:mCherry ci5 ; fli1a:negfp y7 ) embryos. The loss of cpn1 showed reduced ISV cells significantly compared to wild-type controls ( Fig. 3F -G,F′,G′, H n = 12 in cpn1 morphants and n = 10 in wt control, p < 0.0001). In addition, only a small number of ISV cells could reach the top of the embryo to form DLAV, suggesting the impairment of endothelial cell migration in cpn1 morphants.
To confirm a migration defect, we measured the difference of ISV length from 24-28 hpf in the control and cpn1 MO. The difference of ISV length in cpn1 MO is significantly shorter than in the control, indicating the migration ability is impaired ( Fig. 3I-M) . We further demonstrated the proliferation defect in cpn1 MO by examining the expression levels of proliferation marker phosphorylated form of histone H3 (pHH3) and proliferating cell nuclear antigen (PCNA). Immunostaining with proliferation marker anti-phosphohistone 3 antibody recognizes mitotic cells and the amount of mitotic cells in the trunk of cpn1 MO showed fewer red spots compared to the control (arrows in Fig. 3N ,O) and quantitative results in Fig. 3P . In addition, the Western blotting analysis showed pHH3 and PCNA signals are reduced in cpn1 MO ( Fig. 3Q ), suggesting a reduction of cell proliferation. Together, the data suggest that cpn1 is essential for endothelial cell growth for patterning ISV and CVP, likely through the regulation of proliferation and migration of the cells.
Knockdown of cpn1 modulates the expression of vascular markers. The growth defects in ISV and
mispatterning in CVP after the loss of cpn1 suggest that cpn1 is essential for vascular development and likely plays a role in modulating vascular identity. To test this hypothesis, we examined the expression of the vascular markers flk1, flt4, mrc1, stabilin, and ephrinb2 through in situ hybridization and qPCR analysis. We observed that the expression of the venous/ISV markers flt4 and mrc1 was decreased in cpn1 morphants compared to wt controls at 24 hpf (Fig. 4 ). The expression of the arterial marker ephrinb2 and the pan-vascular markers flk1 and stabilin were also reduced by in-situ hybridization. To determine the extent of the decrease in the marker expression, we quantified flt4, ephrinb2, mrc1, stabilin, and flk1 transcript levels through qPCR and determined a 30-40% decrease in the expression in cpn1 morphants, except flk1 (slightly but not significantly decreased). These results suggest that cpn1 regulates several vascular genes to promote vessel formation.
Overexpression of cpn1 also causes vascular defects in zebrafish embryos. Because the loss of cpn1 caused vascular defects, we hypothesized that cpn1 overexpression might promote vascular growth. We overexpressed cpn1 by injecting 0.3~0.93 ng of mRNA (represent as cpn1 mRNA) into transgenic Tg (kdrl:EGFP) embryos or overexpressed cpn1 under the control of the fli1a promoter in transgenic embryos (represent as (fli:cpn1)). Overexpression of cpn1 showed normal morphology at 28 hpf ( Fig. 5A-C) . Surprisingly, the overexpression of cpn1 resulted in ISV growth defects and CVP mispatterning ( Fig. 5D -L). While injection of cpn1 mRNA into embryos, a high percentage of ISV showed stalling growth at the mid-somite and did not reach DLAV compared to uninjected controls at 28 hpf ( Fig. 5D ,E). Quantitative results showed over 95% complete ISVs in uninjected controls (n = 18 embryos) and only ~20% complete ISVs (n = 28 embryos) in cpn1 mRNA-injected embryos (Fig. 5O ). In addition, we observed defects in CVP formation in cpn1-overexpressing embryos. Compared with uninjected controls in CVP region from 28-48 hpf, we observed less or no endothelial cell sprouting at 28 hpf and less honeycomb-like capillary loop formation at 48 hpf ( Fig. 5G-L) . The quantification of CVP loop formation showed a decrease in cpn1 mRNA embryos (n = 19) at 48 hpf (Fig. 5P ). In addition, injection of cpn1 mRNA into Tg(kdrl:mCherry ci5 ; fli1a:nEGFP y7 ) embryos shows that the cell numbers per ISV was lower and the ISVs did not reach DLAV when compared to uninjected wt control at 30 hpf (Fig. 5M,N,Q) . We evaluated whether cpn1 overexpression in embryos increases cell death. The TUNEL assays revealed no significant apoptotic cells in cpn1-overexpressing fish compared with that in wt controls (data not shown). Together, the data suggest that cpn1 overexpression can disrupt endothelial cell growth for vascular patterning, likely through the regulation of cell proliferation and migration.
Consistent with the defects of the vasculature in cpn1-overexpressing embryos, we observed that cpn1 overexpression also causes circulation defects and pericardial edema (sFig. 6). The injection of cpn1 mRNA into Tg (fli1a:eGFP y1 ; gata1:dsRed sd2 ) embryos resulted in circulation defects observed as limited blood flow in the aorta-vein and ISV-DLAV at 48 hpf (sFig. 6A-C). Furthermore, compared with controls (n = 33), 70% cpn1 mRNA-injected embryos (n = 28) had pericardial edema at 72 hpf (sFig. 6D-F). Because both loss or gain of cpn1 function causes vascular defects, cpn1 may have a critical role in controlling ISV and CVP formation and thus should be fine-tune regulated.
Although the overexpression of cpn1 impairs vascular development, we found embryos with a low level of cpn1 mRNA (<200 pg) injection did not show vascular defects. Thus, we can perform a rescue experiment to confirm whether the vascular defects were specifically caused by morpholino knockdown. We injected 100 pg cpn1 mRNA in the control embryos and cpn1 e1i1 morphant and found that the overexpression of cpn1 mRNA in cpn1 e1i1 MO restores ISV growth by 35% compared to the injection of cpn1 morpholino alone (cpn1 e1i1 MO) at 30 hpf (sFig. 7A-E), while the overexpression of cpn1 in control embryos had no obvious effect on the vascular development (sFig. 7B) compared to the uninjected controls (sFig. 7A). The data specifically confirm that the knockdown of cpn1 impaired vascular development.
Gain of cpn1 function alters the expression of vascular markers. The overexpression of cpn1 causes
ISV growth defects and CVP mispatterning, suggesting that the overexpression of cpn1 can modulate vascular identity. To test this hypothesis, we examined the expression of the vascular markers flk1, flt4, mrc1, stabilin, and ephrinb2 through the in situ hybridization or qPCR. We observed that the expression of the venous/ISV markers flt4, mrc1, and dab2 was lower in cpn1-overexpressing fish than in wt controls at 24 hpf; whereas the expression of the arterial marker ephrinb2 remained unchanged. (sFig. 8A-F,K). In addition, the expression of the pan-vascular markers flk and stabilin at the vessels and CVP was no-to-slightly increased in embryos (sFig. 8G-J). These results suggest that overexpression of cpn1 has a higher impact on venous genes than on arterial genes to regulate vascular development. The remodeling expression pattern of vascular markers was different from that after cpn1 knockdown, indicating that differential mechanisms that control vascular development in cpn1-overexpressing endothelial cells.
Carboxypeptidase activity is crucial for vascular development. Cpn1 is required for vascular development and cpn1 encodes carboxypeptidase N peptide 1, the enzyme activity site, suggesting that carboxypeptidase activity is crucial for vascular development. The tetramers of carboxypeptidase N are composed of 2 Cpn1 active subunits and 2 Cpn2 regulatory subunits. To evaluate whether carboxypeptidase activity is crucial for vascular development, we inhibited carboxypeptidase N activity by using the protamine treatment 23 . After the addition of 0.01 mg/ml protamine into the fish medium, we found no morphological difference in the control and protamine-treated embryos (Fig. 6A,B) ; however, we observed stalling of ISVs with 74% decrease in ISV completion and CVP mispatterning in embryos (Fig. 6D ,F) compared with that in untreated embryos (Fig. 6C,E ). We confirmed that protamine treatment dose-dependently impairs vascular development (data not shown).
Interaction among cpn1 and multiple signals. We observed that the overexpression or knockdown of cpn1 impaired ISV growth and caused CVP defects. Notch signaling is crucial for aorta-vein identity and ISV growth with the interaction of VEGFR2 signaling in the trunk of zebrafish. In addition, BMP signaling regulates angiogenic sprouting from the posterior cardinal vein to form CVP, which is a distinct mechanism of angiogenesis from ISV growth 15 . Thus, we investigated the regulatory relationship between cpn1 and Notch or VEGFR2. We inactivated Notch and VEGFR2 signaling through exogenous DAPT and SU5416 24 treatment, respectively ( Fig. 7A-C) . We observed that cpn1 expression was downregulated when Notch or VEGFR2 signals were inhibited in the trunk area. Interestingly, in the tail region, the expression of cpn1 was ectopic in SU5416 or DAPT-treated embryos. The transverse sections of the embryo trunk and the tail region confirmed this observation ( Fig. 7D-I) . The data suggest that cpn1 controls vascular growth likely regulated by Notch and VEGF pathways in the trunk.
Wiley and co-workers reported that BMP signaling pathways regulate sprouting angiogenesis from the axial vein to form CVP, which provides a distinct mechanism of angiogenic sprouting. We examined whether cpn1 interacts with BMP signal functioning in CVP formation by using DMH1 (4-(6-(4-isopropoxyphenyl) pyrazolo (1, 5-a) pyrimidin-3-yl) quinoline), which inhibits activin receptor-like kinase 2/3 and DM to inhibit BMP receptor 2 (BMPR2) signals 25 . Compared with the DMSO controls, the expression level of cpn1 remained unchanged after DM or DMH1 treatment in the trunk and tail regions ( Fig. 7J-L) . The data suggest that cpn1 is not regulated by BMP signals. Instead, we examined whether Cpn1 could regulate BMP signals. The qPCR analysis results showed that a decreased expression of the Notch downstream target gridlock and BMP regulated targets id1, eve1 and gata2, suggesting the regulatory role of cpn1 (Fig. 7S ). In addition, the Western blot analysis showed the reduced phosphorylation of Smad1/5/8 (the main effectors of BMP signal), total and phosphorylated Erk1/2 in cpn1 morphants compared to the controls (Fig. 7T) . The decreased expression of gridlock mRNA and Erk1/2 protein suggest the Cpn1 controls ISV mediated with Notch/VEGF signals. The reduced mRNA expression of In summary, the knockdown or overexpression of cpn1 caused vascular defects, suggesting the role of cpn1 in controlling ISV and CVP growth through a fine-tuned regulation. In addition, cpn1 regulates vascular development mediated by distinct signals at different localizations in zebrafish.
Discussion
This study shows that cpn1 mRNA is expressed in developing vessels. The knockdown of cpn1 through an injection of morpholino caused vascular defects, suggesting the role of cpn1 in controlling ISV and CVP growth. We have demonstrated that vascular defects in cpn1 morphants are caused by the impairment of migration and proliferation but not by nonspecific cell death. In addition, cpn1 MO knockdown acted specifically and the expression level of vascular markers changed in cpn1 MO. The results suggest that cpn1 is essential for vascular development. Furthermore, the overexpression of cpn1 impaired the growth of ISV and CVP by reducing ISV cell proliferation rather than cell death. The remodeling expression of vascular markers was different from the knockdown of cpn1, indicating that different mechanisms control vascular patterning in cpn1-overexpressing cells. Finally, we explored the regulation of cpn1 mediated by VEGF and Notch signals in the trunk, which is crucial for ISV growth. In the tail region, cpn1 functions in CVP formation likely through interacting with BMP signals. Together, we observed that loss and gain of cpn1 function caused vascular defects and revealed a fine-tuned regulation of cpn1 that controls vascular patterning mediated by multiple signals at different localizations in zebrafish.
Our previous studies found the vascular functions of Isl2 and Nr2f1b are mediated by Notch signaling 18, 19 . In this study, we demonstrated that cpn1 functions in the vasculature are mediated by VEGF and Notch signals. Our transcriptomal analysis suggests that cpn1 is likely regulated by Isl2/Nr2f1b. Interestingly, we determined several consensus binding sites of Isl2 or Nr2f located within the 5-kb upstream sequence of cpn1 by using the sequence analysis software Regulatory Sequence Analysis Tool (RSAT). Future studies will examine the direct or indirect interaction of isl2/nr2f1b and cpn1 genes. Because increased or decreased expression of cpn1 can cause vascular defects, other regulators that control cpn1 expression may be present in addition to Isl2 and Nr2f1b. Promoter sequence analysis can provide information on the crucial regulatory region or sequence and help in determining new regulators for the specific cpn1 gene other than Isl2 or Nr2f1b.
Carboxypeptidase N is a plasma metalloprotease and is composed of 2 catalytic activity subunits (cpn1) and 2 regulatory subunits (cpn2). Carboxypeptidase N is critical for zebrafish liver development 20 . Moreover, it has been reported that carboxypeptidase N is responsible for the C-terminal cleavage of SDF-1a in the circulation 21 . SDF1a and its receptor, CXCR4, are key regulators of the hematopoietic, nervous, and cardiovascular systems during embryogenesis, which is essential for hematopoiesis, lymphocyte homing, pre-B-cell growth, and angiogenesis 26, 27 . However, no study has yet reported the role of Cpn1 in vascular function. Thus, our study is the first to report the contribution of cpn1 in vascular development and we hypothesize that cpn1 might contribute vascular growth by controlling SDF1a-cxcr4 signals. In this study, we also revealed that cpn1 regulates vascular development mediated by distinct signals at different localizations in zebrafish. We found cpn1 expression is down regulated in the trunk region when VEGF or Notch pathways are inhibited whereas it is ectopically expressed under the same conditions in the tail region. These results are consistent with our data that loss of cpn1 causes ISV growth defects in the trunk while ectopically expression of cpn1 in the tail likely interferes BMP signals to inhibit EC sprouting and migration at CVP. However, the substrates/targets of Cpn in those signals remain to be elucidated.
Carboxypeptidase N is also known as kininase-1 and anaphylatoxin inactivator and is crucial in the regulation of peptides such as bradykinins and anaphylatoxins. The peptide bradykinin dilates blood vessels and thus reduces blood pressure. Angiotensin-converting enzyme (ACE) inhibitors, a class of anti-hypertensive drugs, lower blood pressure by stabilizing bradykinin [28] [29] [30] . However, the regulation of bradykinin by CPN is not fully described. Thus, the relationship among Cpn1, bradykinin, and hypertension (HTN) should be investigated in the future, and Cpn1 can potentially serve as a biomarker for HTN. Mutations in cpn1 have been associated with angioedema or chronic urticaria caused due to carboxypeptidase N deficiency 31, 32 . Rapidly progressing angioedema is treated as a medical emergency because of the risk of suffocation. However, mechanistic reasons and their regulatory pathways remain unknown. One possible mechanism is that CPN1 deficiency causes the dilation of blood vessels because of the high level of bradykinin accumulation. Long-term dilation of blood vessels can cause angioedema. Meanwhile, dilated vessels can increase immunocyte penetration, and a complement system can result in urticaria. HTN is a major risk factor for cardiovascular diseases and is probably caused by complex interactions among genetic and environmental factors. Angioedema is the rapid allergic swelling of the dermis and subcutaneous tissues. Our study results facilitated an understanding of molecular mechanisms underlying the association of cpn1 with HTN and angioedema. Thus, we hypothesized that prolonged cpn1 deficiency and cpn1 overexpression in animals can respectively cause HTN and angioedema and this hypothesis will be tested in future studies. The use of zebrafish as a model allows for the generation of transgenic or knockout animal models for studying cpn1-related HTN and angioedema. Thus, cpn1 might be used as a novel biomarker and therapeutic target for HTN and angioedema.
Our study highlights new pathways and molecular mechanisms leading to vascular patterning by carboxypeptidase N. Studies on vascular development have high potential medical relevance. Cardiovascular diseases are a major cause of death worldwide. Embryonic vascular development has applications in human congenital and acquired vascular diseases. and some zebrafish vascular mutants have been characterized as models for human congenital disorders. Our results show that, in clinical practice, cpn1 can be a potential biomarker or therapeutic target for vascular diseases such as HTN, angioedema, and urticaria.
Methods

Zebrafish husbandry. Zebrafish (Danio rerio) wildtype Tupfel Long Fin (TL) or the transgenic (Tg) lines
Tg (kdrl:eGFP) la116 , Tg (kdrl:mCherry) ci5 , Tg (gata:dsRed) sd2 , Tg (fli1a:egfp) y1 , and Tg (fli1a:negfp) y7 have been described [33] [34] [35] [36] [37] . Fish and embryos were raised and maintained at 28.5 °C under a 14-h light/10-h dark photoperiod according to the zebrafish book guildline 38 with approval from the National Sun Yat-sen University Animal Care Committee (approval reference #10231).
Chemical treatment. Endogenous pigmentation was blocked by adding 0.003% N-phenylthiourea (PTU; Sigma) to E3 media at 6hpf. The embryos were treated with the VEGF inhibitor SU5416 (15 μM, Calbiochem), Notch signal inhibitor DAPT (75 μM, Sigma), and protamine (0.01 mg/mL, Sigma) at a working concentration in E3 medium at 6 hpf. To block BMP signals, the embryos were treated with dorsomorphin (DM, 10 μM, Calbiochem) and DMH1 (40 μM, Calbiochem) at a working concentration at 20 hpf. The control embryos were treated with an equivalent concentration of 0.3% DMSO.
In situ hybridization. Whole-mount in situ hybridization was performed according to the method described in refs 39, 40. Probes for cpn1 were obtained through PCR by using primers listed in Table S1 and through in vitro transcription by using T7 Polymerase (Roche) with digoxigenin-labelled UTP. The probes flk, flt4, mrc1, stabilin, and ephrinb2 have been described 18, 33 . Briefly, the embryos were fixed in 4% paraformaldehyde and stored at −20 °C in methanol until use. After rehydration, permeabilization, probing with target mRNA overnight, washing, and blocking with 1% BSA, an AP-conjugated antidigoxigenin antibody was added and subsequently reacted with the NBT/BCIP substrate (Roche). The stained embryos were embedded in 3% methylcellulose and photographed using the Zeiss Axiocam HR camera (Carl Zeiss) on the Zeiss Lumar V12 stereomicroscope. For transverse sections, the embryos were fixed in the tissue freezing medium Tek OCT Compound and sectioned at 10 µm by using the Leica CM3050S cryostat and photographed on the IX71 inverted microscope (Olympus) by using the SPOT RT3 camera (Diagnostic Inc.).
Confocal imaging.
For confocal images, the embryos were immobilized and embedded in 1.5% low-melting-point agarose with 5% tricaine (Invitrogen), and images were obtained on the Zeiss LSM700 or Nikon Eclipse 90i C1 confocal microscopes and processed using the ImageJ software (NIH, USA). The counting area was between the 5 th and 15 th ISVs of the 24-72-hpf embryos. The number of cells in the ISVs was determined by counting cells in the individual slices of confocal stacks. Final figures were processed using Adobe Photoshop.
Morpholino and Tol2 DNA Injections. Morpholinos for each gene were obtained from Gene-Tools, LLC (Philomath, OR). The following sequences of morpholino oligonucleotides were used:
p53 MO: 5′-GCGCCATTGCTTTGCAAGAATTG-3′ Standard control MO sequence: 5′-CCTCTTACCTCAGTTACAATTTATA-3′ cpn1 ATG MO (5ʹ-GAGCTGCCTGACAGCATGGTCCCA-3ʹ) to block translation and cpn1 i1e1 MO (5ʹ-AGAGTAAACACAAGACTCACATGTT-3ʹ) to target the boundary of the intron 1 and exon 1 to interfere with its splicing. The microinjections of morpholino oligonucleotides were administered as previously described. Briefly, morpholinos or expression vectors were injected into the embryos in the 1-2-cell stage on a 3% agar plate. After injections, the embryos were cultured in E3 buffer until examination.
To generate mRNA-or fli1:cpn1-overexpressing embryos, we used Tol2kit vectors with the multisite Gateway cloning system (Invitrogen) to build expression constructs. The cpn1-coding region flanking with attb1/b2 sequences was amplified from cDNA by using primers listed in Table S1 to generate pDONR-cpn1. A Gateway-compatible 0.8-kb fli1 promoter has been described 41 . Approximately 100 pg of plasmid DNA was coinjected with 40 pg of transposase mRNA into embryos at the 1-cell stage. The success of transgenesis was verified in transient (fli1:cpn1)-overexpressing embryos that express cardiomyocyte light chain 2 (cmlc2) driven GFP from the pDEST-Tol2-CG2 vector backbone. In addition, capped and polyadenylated mRNA of cpn1 was synthesized using in vitro mMESSAGE mMASCHINE transcription kit with SP6 RNA polymerase (Ambion).
RNA extraction and quantitative real-time PCR. Total RNA was extracted from approximately 50 embryos at designated stages by using the RNeasy mini kit (Qiagen), and cDNA was prepared using Reverse Transcriptase and oligo-dT primer (Roche) according to manufacturer instructions. Quantitative real-time PCR was performed using the LightCycle 96 instrument (Roche) with SYBR Green I Master (Roche). The qRT-PCR primers for zebrafish are listed in Table S1 . Relative gene expression levels were analyzed using the ΔΔ C t method, and β-actin was used as a reference gene. All experiments were performed in biological triplicates from three independent batches.
Acridine orange staining and TUNEL assay. The dechorionated embryos were soaked in E3 medium containing 2 µg/ml acridine orange for 30 min. After washing 6 times with fresh E3 medium, the embryos were mounted in 3% methylcellulose with 5% tricaine and photographed.
TUNEL assay was performed to analyze apoptosis in the embryos. The 30 hpf embryos were fixed in 4% paraformaldehyde overnight, dehydrated in methanol, and stored at −20 °C. The embyros were rehydrated and treated with 10 µg/ml proteinase K for 20 min at room temperature before labelling DNA breaks with terminal deoxynucleotidyl transferase and fluorescein-dUTP (Roche) according to manufacturer instructions. For fluorescence signal detection, the embryos were blocked in 5% sheep serum (SS), incubated with peroxidase-conjugated antifluorescein antibody (diluted 1:2000; Roche) overnight at 4 °C, washed, and visualized using the DAB color development kit (Roche).
Protein Extraction and Western Blotting. Embryos lysates were prepared using RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM PMSF and protease inhibitors) and phosSTOP (Roche). The lysates were spin down, added SDS sample buffer and boiled for 10 mins. The proteins were separated by SDS-PAGE and then transferred to a polyvinylidene fluoride (PVDF) membrane (Bio-rad). The membranes were washed in TBS (Tris-buffered saline) with Tween-20 (TBST) and blocked with nonfat milk in TBST for 1 hr. The membranes were then incubated with anti-phospho histone H3 (pHH3) (Millipore), anti-Histone H3, anti-Erk1/2 and anti-phospho-Erk1/2 (Cell Signaling Technology), anti-PCNA, anti-Samd1/5/8 and anti-phospho-Samd1/5/8 (Santa Cruz Biotechnology) polyclonal antibodies and anti-β-actin monoclonal antibody (Sigma) overnight at 4 °C. The membranes were washed with TBST and incubated with a peroxidase conjugated secondary antibody (Cell Signaling Technology) at room temperature for 2 h. The signal was detected by ECL chemiluminescence (Bio-Rad).
Anti-phospho histone H3 staining. Embryos were fixed with PFA, permeabilized with pre-chilled acetone for 10 min, washed in PBS with 0.1% Tween-20 (PBSTw), and blocked with 10% normal goat serum (NGS) in PBS with 0.8% Triton X-100 (PBSTx) for 1 h at room temperature. Then, embryos were incubated overnight at 4 °C in the anti-phospho histone H3 polyclonal antibody (Millipore; 1:300 in 1% NGS/PBSTx). After washing 4 times for 10 min each in PBSTw, the embryos were incubated for 2 h at room temperature in the dark with the secondary antibodies (donkey anti-rabbit IgG-CFL 555, Santa Cruz #sc-362271; 1:200 in 1% NGS-PBSTx). Embryos were washed 5 times, embedded in 3% methylcellulose, and photographed using the Zeiss Axiocam HR camera (Carl Zeiss) on the Zeiss Lumar V12 fluorescent stereomicroscope.
